|
Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) DCF Valuation
CN | Healthcare | Biotechnology | SHZ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) Bundle
Designed for accuracy, our (300705SZ) DCF Calculator empowers you to evaluate Hunan Jiudian Pharmaceutical Co., Ltd. valuation using actual financial data, along with the complete flexibility to modify all essential parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 924.1 | 978.2 | 1,627.7 | 2,326.2 | 2,692.5 | 3,573.8 | 4,743.4 | 6,296.0 | 8,356.6 | 11,091.7 |
| Revenue Growth, % | 0 | 5.85 | 66.4 | 42.92 | 15.75 | 32.73 | 32.73 | 32.73 | 32.73 | 32.73 |
| EBITDA | 101.5 | 145.3 | 296.8 | 369.2 | 485.8 | 557.4 | 739.8 | 981.9 | 1,303.3 | 1,729.8 |
| EBITDA, % | 10.98 | 14.85 | 18.23 | 15.87 | 18.04 | 15.6 | 15.6 | 15.6 | 15.6 | 15.6 |
| Depreciation | 37.8 | 49.0 | 54.4 | 60.5 | 72.5 | 126.8 | 168.3 | 223.4 | 296.6 | 393.6 |
| Depreciation, % | 4.1 | 5.01 | 3.34 | 2.6 | 2.69 | 3.55 | 3.55 | 3.55 | 3.55 | 3.55 |
| EBIT | 63.6 | 96.2 | 242.3 | 308.7 | 413.3 | 430.5 | 571.4 | 758.5 | 1,006.7 | 1,336.2 |
| EBIT, % | 6.89 | 9.84 | 14.89 | 13.27 | 15.35 | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 |
| Total Cash | 131.6 | 135.3 | 498.7 | 436.1 | 515.3 | 690.4 | 916.4 | 1,216.3 | 1,614.4 | 2,142.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 149.0 | 189.5 | 284.9 | 503.6 | 625.8 | 699.7 | 928.7 | 1,232.6 | 1,636.0 | 2,171.5 |
| Account Receivables, % | 16.12 | 19.37 | 17.5 | 21.65 | 23.24 | 19.58 | 19.58 | 19.58 | 19.58 | 19.58 |
| Inventories | 136.4 | 153.1 | 214.5 | 241.0 | 265.5 | 456.1 | 605.4 | 803.6 | 1,066.6 | 1,415.6 |
| Inventories, % | 14.76 | 15.65 | 13.18 | 10.36 | 9.86 | 12.76 | 12.76 | 12.76 | 12.76 | 12.76 |
| Accounts Payable | 69.4 | 59.9 | 108.9 | 143.8 | 159.3 | 231.7 | 307.5 | 408.2 | 541.8 | 719.1 |
| Accounts Payable, % | 7.51 | 6.12 | 6.69 | 6.18 | 5.92 | 6.48 | 6.48 | 6.48 | 6.48 | 6.48 |
| Capital Expenditure | -182.0 | -78.4 | -125.9 | -413.4 | -426.8 | -493.6 | -655.2 | -869.6 | -1,154.3 | -1,532.1 |
| Capital Expenditure, % | -19.69 | -8.01 | -7.74 | -17.77 | -15.85 | -13.81 | -13.81 | -13.81 | -13.81 | -13.81 |
| Tax Rate, % | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 |
| EBITAT | 59.5 | 87.1 | 218.8 | 286.9 | 378.5 | 395.1 | 524.4 | 696.0 | 923.8 | 1,226.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -300.7 | -8.9 | 39.5 | -276.3 | -107.1 | -163.8 | -264.9 | -351.6 | -466.7 | -619.4 |
| WACC, % | 6.78 | 6.78 | 6.77 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,479.9 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -644 | |||||||||
| Terminal Value | -23,191 | |||||||||
| Present Terminal Value | -16,708 | |||||||||
| Enterprise Value | -18,188 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | -18,192 | |||||||||
| Diluted Shares Outstanding, MM | 482 | |||||||||
| Equity Value Per Share | -37.76 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled financial data for Hunan Jiudian Pharmaceutical Co., Ltd. (300705SZ).
- Authentic Data: Access to historical performance and future projections (highlighted in the yellow cells).
- Assumption Flexibility: Modify key forecast elements such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Observe how your inputs affect the valuation of Hunan Jiudian Pharmaceutical Co., Ltd. (300705SZ) in real-time.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Interface: Organized for straightforward navigation and ease of use, complete with step-by-step guidance.
Key Features
- Comprehensive Financial Data: Access Hunan Jiudian Pharmaceutical Co., Ltd.'s historical financial statements along with pre-filled projections.
- Customizable Variables: Modify WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Insights: Watch the intrinsic value of Hunan Jiudian Pharmaceutical Co., Ltd. recalibrate instantly.
- Intuitive Visualizations: Dashboard charts provide clear displays of valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and financial experts.
How It Functions
- Download the Template: Gain immediate access to the Excel-based Hunan Jiudian Pharmaceutical DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells to set growth rates, WACC, profit margins, and other key variables.
- Instant Calculations: The model will automatically refresh to display Hunan Jiudian Pharmaceutical’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment strategies or financial evaluations.
Why Opt for Hunan Jiudian Pharmaceutical's Calculator?
- Precision: Utilizes authentic Hunan Jiudian financial data to ensure reliable results.
- Adaptability: Tailored for users to easily modify and test various inputs.
- Efficiency: Eliminate the need to create a DCF model from the ground up.
- Industry Standard: Crafted with the accuracy and usability expected by CFOs.
- Intuitive: Simple to navigate, even for users with limited financial analysis skills.
Who Can Benefit from This Product?
- Investors: Assess the fair value of Hunan Jiudian Pharmaceutical (300705SZ) before making investment choices.
- CFOs: Utilize a high-quality DCF model for financial analysis and reporting tailored to Hunan Jiudian Pharmaceutical (300705SZ).
- Consultants: Seamlessly customize the template for valuation reports catered to clients interested in Hunan Jiudian Pharmaceutical (300705SZ).
- Entrepreneurs: Discover insights into financial modeling practices employed by leading pharmaceutical firms.
- Educators: Implement this resource as a teaching aid to illustrate valuation techniques specific to the pharmaceutical industry.
Overview of Template Components
- Historical Data: Contains past financials and baseline forecasts for Hunan Jiudian Pharmaceutical Co., Ltd. (300705SZ).
- DCF and Levered DCF Models: Comprehensive templates designed to assess the intrinsic value of Hunan Jiudian Pharmaceutical Co., Ltd. (300705SZ).
- WACC Sheet: Built-in calculations to determine the Weighted Average Cost of Capital.
- Editable Inputs: Adjust essential parameters such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A thorough analysis of the financials for Hunan Jiudian Pharmaceutical Co., Ltd. (300705SZ).
- Interactive Dashboard: Dynamic visualization of valuation outcomes and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.